Fresh funding backs a high-stakes attempt to do what current amyloidosis drugs still cannot: clear the buildup already damaging the heart.
UK-based biotech Immutrin has raised $87 million (£65 million) in an oversubscribed Series A round to push forward a next-generation antibody therapy aimed at a stubborn gap in amyloidosis treatment: removing the harmful protein buildup already lodged in patients’ tissues.
The financing, announced this week, will fund the company’s lead program through clinical proof of concept in ATTR cardiomyopathy, a serious and often fatal form of amyloidosis that can progressively weaken the heart [1].
In biotech, many drugs can slow disease progression. Far fewer are built to try to undo the damage it has already done.
Amyloidosis is a group of rare, progressive diseases caused by proteins that misfold, clump together and settle into organs like biological debris. In ATTR cardiomyopathy, debris accumulates in the heart, gradually making it stiffer and less able to pump effectively.
The simplest way to understand the current treatment landscape is this: some therapies can help turn off or reduce the source of the mess, but they do not necessarily clean up what is already there. That is the opening Immutrin is chasing.
Immutrin’s lead antibody is designed to selectively bind to amyloid fibrils – the abnormal protein clumps themselves – and trigger the body’s immune system to help remove them from tissue. In plain terms, the company is not just trying to stop more buildup. It is trying to help the body haul away the old wreckage.
If that works in humans, it could mark a meaningful shift for patients with more advanced disease, where existing deposits may continue to drive organ dysfunction even after protein production is slowed.
Immutrin CEO Mihriban Tuna framed the raise as validation not only of the company’s science, but of the commercial and clinical opportunity ahead.
“Having been involved in building Immutrin from its earliest days, I’m delighted to welcome support from our new and existing investors in this strong global syndicate,” she said. “The depth of investor confidence speaks to the strength of our approach, the clear differentiation of our lead asset, and the genuine opportunity to transform outcomes for patients with ATTR amyloidosis.”
It is ambitious, but not unusual in a field where incremental gains have already changed the standard of care, yet left patients and clinicians asking what comes next.
Sef Kurstjens, who serves as the Chair of the Board at Immutrin, highlighted the ongoing challenges in treating amyloidosis, noting that it remains a field with significant unmet clinical needs, especially for individuals with advanced stages of the disease caused by existing amyloid deposits.
Kurstjens explained that Immutrin’s primary therapeutic candidate is designed to clear these large, established deposits more efficiently than rival antibody treatments currently under development. Moreover, Kurstjens emphasized that this asset could be a valuable addition to existing therapies that aim to suppress further amyloid production.
That “complementing” aspect is key. Immutrin is not necessarily positioning itself as a replacement for current ATTR drugs, but as a potential partner to them – one therapy to reduce new damage, another to help reverse old damage.
Series A rounds of this size are also about timing. ATTR amyloidosis has become one of the more closely watched spaces in cardiometabolic and aging-adjacent biotech, in part because better diagnostics and growing clinical awareness are bringing more patients into view. As the field matures, investor attention is shifting from disease suppression toward something more ambitious: reversal. It is the word to watch.
For longevity investors, Immutrin’s raise lands squarely in a familiar but increasingly important category: therapies that aim not just to slow decline, but to restore function after biological damage has accumulated.
Amyloid buildup is not simply a rare-disease problem; it is part of a broader conversation about what happens when the body’s maintenance systems fail over time. In that sense, Immutrin’s approach taps into a core longevity thesis: healthy aging may depend as much on clearing harmful cellular and molecular debris as it does on preventing its formation in the first place.
Whether Immutrin can deliver on that promise remains a clinical question. However, the size of this round suggests investors believe the next frontier in amyloidosis – and perhaps in longevity medicine more broadly – is no longer just damage control. It is repair.
Image courtesy of Immutrin
[1] https://www.immutrin.com/assets/pdf/Immutrin-Press-Release-240326.pdf
